moxetumomab pasudotox

Ligand id: 7675

Name: moxetumomab pasudotox

References
1. Beers R, Kreitman RJ, Pastan IH, Salvatore G. (2003)
Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells.
Patent number: WO2003027135. Assignee: Beers R, Kreitman RJ, Pastan IH, Salvatore G, US Gov Health & Human Serv. Priority date: 26/09/2001. Publication date: 03/04/2003.
2. Kreitman RJ, Pastan I. (2011)
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
Clin. Cancer Res., 17 (20): 6398-405. [PMID:22003067]
3. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I. (2012)
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
J. Clin. Oncol., 30 (15): 1822-8. [PMID:22355053]
4. Onda M, Nagata S, FitzGerald DJ, Beers R, Fisher RJ, Vincent JJ, Lee B, Nakamura M, Hwang J, Kreitman RJ et al.. (2006)
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
J. Immunol., 177 (12): 8822-34. [PMID:17142785]
5. Pastan IH, Ho M, Bang S. (2011)
Mutated anti-cd22 antibodies and immunoconjugates.
Patent number: US7982011. Assignee: The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services. Priority date: 25/11/2003. Publication date: 19/07/2011.
6. Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I. (2002)
Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
Clin. Cancer Res., 8 (4): 995-1002. [PMID:11948105]
7. Yates SP, Merrill AR. (2004)
Elucidation of eukaryotic elongation factor-2 contact sites within the catalytic domain of Pseudomonas aeruginosa exotoxin A.
Biochem. J., 379 (Pt 3): 563-72. [PMID:14733615]